治疗肺动脉高压新药Selexipag的研究进展  

Advances in Research on Selexipag, a New Drug for Pulmonary Hypertension

作　　者：钱清华[1] 桂玉梅[1] 高慧 QIAN Qing-hua;GUI Yu-mei;GAO Hui(School of Medicine and Chermical Engineering,Lianyungang Technical College,Lianyungang 222006,China)

机构地区：[1]连云港职业技术学院医药与化学工程学院,江苏连云港222006

出　　处：《连云港职业技术学院学报》2018年第2期1-6,共6页Journal of Lianyungang Technical College

基　　金：江苏省高等学校大学生创新创业训练计划项目(201711050002Y)

摘　　要：肺动脉高压(PAH)是以肺血管阻力增加导致右侧心力衰竭的进行性疾病。Selexipag是一种口服的选择性前列环素受体激动剂,用于PHA的靶向治疗,对其作用机制、药动学、药效学、临床试验、用法与用量、药物相互作用、安全性以及特殊人群用药等方面的研究表明,该药具有选择性高、作用时间长等特点,可用作PHA一线治疗的靶向药物。Selexipag的晶态对药效有一定的影响,Selexipag及其中间体的合成工艺需要进一步研究,对合成Selexipag原料药的不同工艺中残留溶剂的检测方法也需要建立。Pulmonary Arterial Hypertension(PAH)is a progressive disease of right heart failure caused by increased pulmonary vascular resistance.Selexipag is an oral selective prostacyclin receptor agonist,a targeted therapy for PHA.Studies on pharmacokinetics,pharmacodynamics,clinical trials,usage and dosage,drug interactions,safety,and drug use in special populations have shown that the drug is characterized by high selectivity and long duration of action,used as a first-line targeted therapy for PHA.The crystal state of Selexipag has a certain effect on the pharmacodynamics.Selexipag and the synthetic process of its intermediates need to be further studied,and the methods for the determination of residual solvents in different processes for the synthesis of Selexipag are also needed.

关 键 词：肺动脉高压 前列环素受体激动剂 赛乐西帕 分子靶向治疗 

分 类 号：R97[医药卫生—药品]